Pharmaceuticals

4Front Ventures Corp.

4Front Ventures Corp Provides Update on Takeover Proceedings and Board Resignations

4Front Fails to Submit Reports Due to Audit Delays

4Front Ventures Corp. Announces Major Board Changes and Postponement of Financial Statements

4Front Ventures Corp. released FY2024 Q3 earnings on November 14 After-Market (EST), actual revenue 17.13 MUSD (forecast 27.5 MUSD), actual EPS -0.007 USD

4Front Ventures Corp. released FY2024 Cumulative 3Q earnings on November 14 After-Market (EST), with actual revenue of 54.63M USD and EPS of -0.0345

4Front Ventures Corp. to Release FY2024 Q3 Earnings on November 14 After-Market EST, Forecast Revenue 27.5 M USD

4Front Ventures Corp. Q2 Revenue Declines 31%

4Front Ventures Corp. launches new product Smoke

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

4Front Ventures Corp.(FFNTF.US)